Literature DB >> 3478544

Iatrogenic and idiopathic acute myelogenous leukemia: a comparison of clinical features and treatment complications.

C K Williams1, J Cuttner, T Ohnuma, E P Ambinder, P P Ferreira, J F Holland.   

Abstract

We have compared the clinical and laboratory features as well as treatment complications observed in 6 patients with iatrogenic acute myelogenous leukemia (I-AML) with those of 26 patients with idiopathic acute myelogenous leukemia (AML). I-AML patients were significantly younger and their disease appeared less virulent on admission than in the AML patients. Following identical chemotherapy, hemorrhagic complications and the need for platelet support were found to be similar for both groups. Major infections, including systemic candidiasis and Gram-negative septicemias, occurred 3 times more frequently among I-AML than AML patients. More marked suppression and delayed regeneration of the bone marrow also occurred in I-AML patients. These observations and other factors, such as post-splenectomy state and inherent immune deficiency among surgically staged lymphoma patients as well as radiation induced immunologic impairment, may have contributed to the increased propensity to develop infection observed in this group of patients. Five of the 6 I-AML and 17 of the 26 AML patients achieved remission. We attribute the satisfactory outcome in our I-AML patients to treatment in a protective environment and availability of facilities for hematologic supportive care.

Entities:  

Mesh:

Year:  1987        PMID: 3478544     DOI: 10.1007/BF02934941

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  24 in total

1.  Cure of Burkitt's lymphoma. Ten-year follow-up of 157 Ugandan patients.

Authors:  J L Ziegler; I T Magrath; C L Olweny
Journal:  Lancet       Date:  1979-11-03       Impact factor: 79.321

2.  Acute leukemia after treatment of lymphoma.

Authors:  J D Rowley; H M Golomb; J Vardiman
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

Review 3.  Hodgkin's disease and acute leukemia. Report of eight cases and review of the literature.

Authors:  F Rosner; H Grünwald
Journal:  Am J Med       Date:  1975-03       Impact factor: 4.965

4.  Impaired humoral immunity in treated Hodgkin's disease.

Authors:  S A Weitzman; A C Aisenberg; G R Siber; D H Smith
Journal:  N Engl J Med       Date:  1977-08-04       Impact factor: 91.245

Review 5.  Chemotherapy of testicular cancer: from palliation to curative adjuvant therapy.

Authors:  E M Jacobs; F M Muggia; M Rozencweig
Journal:  Semin Oncol       Date:  1979-03       Impact factor: 4.929

6.  Therapy of secondary acute nonlymphocytic leukemia with cytarabine.

Authors:  H D Preisler; A P Early; A Raza; G Vlahides; M J Marinello; A M Stein; G Browman
Journal:  N Engl J Med       Date:  1983-01-06       Impact factor: 91.245

7.  A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients.

Authors:  J W Yates; J F Holland
Journal:  Cancer       Date:  1973-12       Impact factor: 6.860

8.  Filtration leukapheresis for granulocyte transfusion therapy. Clinical and laboratory studies.

Authors:  D J Higby; J W Yates; E S Henderson; J F Holland
Journal:  N Engl J Med       Date:  1975-04-10       Impact factor: 91.245

9.  Acute myeloblastic leukemia following treatment for non-hematopoietic cancers: report of 19 cases and review of the literature.

Authors:  M H Zarrabi; F Rosner
Journal:  Am J Hematol       Date:  1979       Impact factor: 10.047

Review 10.  Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical features and response to therapy.

Authors:  H D Preisler; G H Lyman
Journal:  Am J Hematol       Date:  1977       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.